MedPath

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

Phase 3
Not yet recruiting
Conditions
CMV Infection
Interventions
Registration Number
NCT06341686
Lead Sponsor
Hospital do Rim e Hipertensão
Brief Summary

The two main cytomegalovirus (CMV) prevention strategies are prophylaxis and preemptive therapy. Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT), but is associated with high rates of neutropenia and late onset of post-prophylactic disease. In contrast, preemptive therapy has the advantage of leading to lower rates of CMV disease and robust humoral and T-cell responses. It is widely used in hematopoietic cell transplant recipients, but is rarely used after solid organ transplant recipients due to logistical considerations.

Detailed Description

Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Kidney transplant or re-transplant recipients, aged ≥18 years;
  • Undergoing induction therapy with anti-thymocyte globulin;
  • Receiving maintenance treatment with Tacrolimus, Mycophenolate and Prednisone;
  • Positive CMV serology for donor and recipient.
Read More
Exclusion Criteria
  • CMV serology positive for donor and negative for recipient;
  • Multiple organ recipients, or other organs
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LetermovirLetermovir 480 MGPatients randomized to the prophylaxis group: Letermovir 480mg, 1x/day, from D14 to D98. Letermovir prophylaxis will start on day 14 after kidney transplantation. In both groups, CMV DNAemia will be monitored weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98), and after any acute rejection treatment occurring between 3 months and 6 months after kidney transplantation.
Preemptive therapyGanciclovirPatients randomized to the preemptive treatment group: Preemptive treatment (PET) will begin on day 21, assessing CMV DNAnemia weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 e 98). The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection). measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).c. In both groups, CMV DNAemia will be monitored weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98), and after any acute rejection treatment occurring between 3 months and 6 months after kidney transplantation.
Primary Outcome Measures
NameTimeMethod
Incidence of CMV syndrome or disease6 months after transplantation

Proportion (%) of CMV syndrome or disease

Secondary Outcome Measures
NameTimeMethod
Incidence of patients with plasma CMV DNAemia > 200 IU3 months

Proportion (%) of patients with plasma CMV DNAemia \> 200 IU

Incidence of patients with CMV infection/syndrome/disease84 Days

Proportion (%) of patients with CMV infection/syndrome/disease

© Copyright 2025. All Rights Reserved by MedPath